Mounjaro 5 mg kwikpen

Mounjaro 5 mg KwikPen contains tirzepatide, a dual GIP and GLP-1 receptor agonist used for the management of type 2 diabetes and, in some regions, for chronic weight management. It helps lower blood sugar by increasing insulin release when glucose levels are high, reducing glucagon secretion, slowing gastric emptying, and suppressing appetite. The 5 mg dose is typically an early maintenance dose after the initial 2.5 mg starting dose. It is administered once weekly using a prefilled KwikPen. In addition to improving glycemic control, it may support significant weight reduction and better metabolic outcomes. Common side effects include nausea, vomiting, diarrhea, and decreased appetite, and it should be used under medical supervision.